Proto-Oncogene Proteins c-mdm2
"Proto-Oncogene Proteins c-mdm2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An E3 UBIQUITIN LIGASE that interacts with and inhibits TUMOR SUPPRESSOR PROTEIN P53. Its ability to ubiquitinate p53 is regulated by TUMOR SUPPRESSOR PROTEIN P14ARF.
| Descriptor ID |
D051736
|
| MeSH Number(s) |
D08.811.464.938.750.562 D12.776.624.664.700.185 D12.776.660.764
|
| Concept/Terms |
Proto-Oncogene Proteins c-mdm2- Proto-Oncogene Proteins c-mdm2
- Proto Oncogene Proteins c mdm2
- c-mdm2, Proto-Oncogene Proteins
- Mdm2 Protein
- Double Minute 2 Protein
- c-mdm2 Proto-Oncogene Protein
- Proto-Oncogene Protein, c-mdm2
- c mdm2 Proto Oncogene Protein
- Murine Double Minute 2 Protein
- Mdm-2 Protein
- Mdm 2 Protein
- MDMX Protein
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-mdm2".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-mdm2".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-mdm2" by people in this website by year, and whether "Proto-Oncogene Proteins c-mdm2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 4 | 4 |
| 1996 | 0 | 8 | 8 |
| 1997 | 0 | 6 | 6 |
| 1998 | 0 | 10 | 10 |
| 1999 | 0 | 6 | 6 |
| 2000 | 0 | 5 | 5 |
| 2001 | 0 | 9 | 9 |
| 2002 | 0 | 10 | 10 |
| 2003 | 0 | 12 | 12 |
| 2004 | 0 | 11 | 11 |
| 2005 | 2 | 5 | 7 |
| 2006 | 12 | 6 | 18 |
| 2007 | 8 | 5 | 13 |
| 2008 | 12 | 2 | 14 |
| 2009 | 7 | 3 | 10 |
| 2010 | 17 | 8 | 25 |
| 2011 | 9 | 8 | 17 |
| 2012 | 8 | 3 | 11 |
| 2013 | 4 | 8 | 12 |
| 2014 | 10 | 5 | 15 |
| 2015 | 6 | 4 | 10 |
| 2016 | 4 | 6 | 10 |
| 2017 | 4 | 1 | 5 |
| 2018 | 3 | 5 | 8 |
| 2019 | 2 | 3 | 5 |
| 2020 | 4 | 2 | 6 |
| 2021 | 2 | 1 | 3 |
| 2022 | 2 | 2 | 4 |
| 2023 | 1 | 3 | 4 |
| 2024 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-mdm2" by people in Profiles.
-
Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies. Cancer Med. 2024 Jul; 13(14):e70028.
-
Treatment options for biliary tract cancer: unmet needs, new targets and opportunities from both physicians' and patients' perspectives. Future Oncol. 2024; 20(20):1435-1450.
-
Age-specific induction of mutant p53 drives clonal hematopoiesis and acute myeloid leukemia in adult mice. Cell Rep Med. 2024 May 21; 5(5):101558.
-
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future. Pharmacol Rev. 2024 May 02; 76(3):414-453.
-
MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action. Cancer Treat Rev. 2024 Jan; 122:102668.
-
Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv. 2023 12; 9(48):eadh1436.
-
Mdm2/p53 levels in bone marrow mesenchymal stromal cells are essential for maintaining the hematopoietic niche in response to DNA damage. Cell Death Dis. 2023 06 23; 14(6):371.
-
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas. J Clin Oncol. 2023 03 20; 41(9):1714-1724.
-
Long non-coding RNA TILR constitutively represses TP53 and apoptosis in lung cancer. Oncogene. 2023 01; 42(5):364-373.
-
Alterations of the Mdm2 C-Terminus Differentially Impact Its Function In Vivo. Cancer Res. 2022 04 01; 82(7):1313-1320.